Physician-executive venture architecture. From a category insight to a clinically validated product in market, for founders building from zero and for companies launching the line they are missing.
Or book a free 20-minute scoping call →You already have the manufacturing, the formulary relationships, and the channel. I help you validate a new category, position it clinically, clear the regulatory path, and get it onto formularies and shelves.
Clinical-nutrition & medtech companiesNo company yet. I take it from the napkin to the market: entity formation, product spec, clinical evidence, regulatory pathway, and a go-to-market that reaches the facility and the shelf.
Founders & first-time buildersA $14B clinical-nutrition industry has never built a good-tasting, clinically designed, diabetes-appropriate frozen dessert, for 40M Americans with diabetes and the 1 in 3 patients in every skilled nursing facility. I mapped the clinical evidence, the FDA food-vs-medical-food pathway, and the channel. Read the analysis and watch the breakdown →
One number up front: the Validation Sprint. From there, we scope only what the evidence supports, and you see the price before you commit.
Not ready to build yet? Start with the Clinical Discovery Sprint, interview-guide review, warm clinical introductions, and synthesis. Flat-fee tiers from $2,500. See Startup Advisory →
All three modules, end to end over ~3–4 months. Scoped from the Validation Sprint’s findings, so you see the full number before you commit to Module 02.
For clinical-nutrition and pharma companies (Fresenius Kabi, Abbott, Nestlé Health Science, Danone Nutricia): start with the $15K Validation Sprint as the wedge, then the build is scoped to enterprise, typically $75K–$250K+ or a $15–30K/month retainer. The sprint gets us in the room; scope prices the rest.
Flat fee, paid at engagement start. No equity, no deferred compensation, no retainer minimums beyond what is stated.
A3HCS sits at the center of a small ecosystem of related entities. Each has a distinct audience and economic model. Brain Revives is the patient and caregiver education arm, related but not the primary commercial path.
Brain Revives is a patient and caregiver education platform for traumatic brain injury, stroke, and acquired brain injury recovery. When an A3HCS engagement touches the home, complex discharge, or post-acute caregiver activation, Brain Revives provides the education infrastructure most health systems do not have time to build internally. Brain Revives is education, not clinical care delivery.
Buyers engage A3HCS directly. Patients and caregivers engage Brain Revives. The arms share a clinical philosophy and a continuity discipline, but distinct audiences and economics.
Visit Brain Revives →One philosophy across four arms . distinct audiences
Physician-executive venture architecture. I take a healthcare category from insight to a clinically validated product in market: validation, entity and product, regulatory pathway, and go-to-market. It serves founders building from zero and established companies launching a new line.
Discovery advisory pressure-tests an existing company’s clinical assumptions. The Venture Build stands up the company or product line itself, from the napkin forward. Discovery starts at $2,500. Venture Build starts with the $15K Validation Sprint.
Yes. Full 0-to-1: entity formation orchestrated, product spec, clinical evidence and protocol plan, regulatory and labeling strategy, financial model, and a go-to-market that reaches the buyer. The spine is the clinical, regulatory, and commercial work a generalist cannot do.
No. No equity, advisory shares, or deferred compensation. All modules are flat fee, paid at engagement start. The recommendation is what the evidence shows, not what benefits an equity position.
In two to three weeks: a category and competitive map, a clinical evidence base, an FDA food-vs-medical-food pathway read, reimbursement and channel viability, and a go/no-go memo with a 12-month build sequence. The fee is creditable toward the build if you proceed.
Yes. For companies like Fresenius Kabi, Abbott, Nestlé Health Science, or Danone Nutricia, the $15K Validation Sprint is the entry point. The build is then scoped to enterprise, typically $75K–$250K+ or a $15–30K/month retainer.
A two-to-four-week structured diagnostic delivered as an executive memo, not a deck. It defines where your system is losing time, margin, and trust, and identifies the two-to-three corrections worth investing in next.